Mucosis B.V. (Groningen, the Netherlands) is an innovative biotechnology company with the ambition to bring to the market high-value vaccines that provide enhanced efficacy and offer easy and painless administration. The company develops new vaccines and improved formulations of existing vaccines. Mucosis' lead programs are focused on the development of an intranasal vaccine to prevent influenza and on the development of a vaccine to prevent pneumococcal diseases. Mucosis exploits a novel and easy-to-apply proprietary technology, Mimopath™. Mucosal vaccines based on this technology raise a more natural immune response and provide a broader base of protection.

Web: www.mucosis.com